Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

Plus, news about Kezar Life Sciences and Concentra Biosciences: Viatris, Lexicon Pharmaceuticals sign licensing deal for cardio drug: Per the agreement, Viatris will pay $25 million ...

Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to ...

Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its ...

The Furman Family announced it purchased Wellington Square, located at 1619 S. Kentucky. The real estate transaction ...

In a report released yesterday, David S Macdonald from Truist Financial maintained a Buy rating on Concentra Group Holdings Parent, Inc. (CON ...

Shares of Concentra Group Holdings Parent, Inc. (NYSE:CON – Get Free Report) have been given an average rating of “Moderate Buy” by the seven analysts that are covering the stock, Ratings reports. One ...